Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
Add more filters










Publication year range
2.
Can Respir J ; 2023: 1422319, 2023.
Article in English | MEDLINE | ID: mdl-37547298

ABSTRACT

Introduction: Cystic Fibrosis Foundation guidelines recommend people with CF perform daily airway clearance. This can be difficult for patients, as some find it time consuming or uncomfortable. Data comparing airway clearance methods are limited. We surveyed patients and their families to understand which methods are preferred and identify obstacles to performing airway clearance. Methods: We designed a REDCap survey and enrolled participants in 2021. Respondents reported information on airway clearance usage, time commitment, and medication use. They rated airway clearance methods for effectiveness, comfort, time commitment, importance, and compatibility with other treatments. The analysis included descriptive statistics and clustering. Results: 60 respondents started and 52 completed the survey. The median patient age was 20 years. Respondents experienced a median of four airway clearance methods in their lifetime, including chest wall oscillation (vest, 92%), manual chest physical therapy (CPT, 88%), forced expiration technique (huff or cough, 77%), and exercise (75%). Past 30-day use was highest for exercise (62%) and vest (57%). The time commitment was generally less than 2 hours daily. Of those eligible for CFTR modulators, 53% reported decreased time commitment to airway clearance after starting treatment. On a scale of 0-100, respondents rated CFTR modulators as their most important treatment (median 99.5), followed by exercise (88). Discussion. Patients and caregivers are familiar with several methods of airway clearance for CF. They report distinct strengths and limitations of each method. Exercise and vest are the most common methods of airway clearance. The use of CFTR modulators may reduce patient-reported time commitment to airway clearance.


Subject(s)
Cystic Fibrosis , Humans , Young Adult , Adult , Cystic Fibrosis/therapy , Cystic Fibrosis Transmembrane Conductance Regulator , Caregivers , Forced Expiratory Volume , Respiratory Therapy/methods
3.
Neurobiol Aging ; 118: 66-76, 2022 10.
Article in English | MEDLINE | ID: mdl-35896049

ABSTRACT

Apolipoprotein E4 (APOE-ε4), the strongest common genetic risk factor for Alzheimer's disease (AD), contributes to worse cognition in older adults. However, many APOE-ε4 carriers remain cognitively normal throughout life, suggesting that neuroprotective factors may be present in these individuals. In this study, we leverage whole-blood RNA sequencing (RNAseq) from 324 older adults to identify genetic modifiers of APOE-ε4 effects on cognition. Expression of RNASE6 interacted with APOE-ε4 status (p = 4.35 × 10-8) whereby higher RNASE6 expression was associated with worse memory at baseline among APOE-ε4 carriers. This interaction was replicated using RNAseq data from the prefrontal cortex in an independent dataset (N = 535; p = 0.002), suggesting the peripheral effect of RNASE6 is also present in brain tissue. RNASE6 encodes an antimicrobial peptide involved in innate immune response and has been previously observed in a gene co-expression network module with other AD-related inflammatory genes, including TREM2 and MS4A. Together, these data implicate neuroinflammation in cognitive decline, and suggest that innate immune signaling may be detectable in blood and confer differential susceptibility to AD depending on APOE-ε4.


Subject(s)
Alzheimer Disease , Apolipoprotein E4/metabolism , Cognitive Dysfunction , Exonucleases/metabolism , Aged , Alzheimer Disease/genetics , Alzheimer Disease/psychology , Brain/physiology , Cognition/physiology , Cognitive Dysfunction/genetics , Genotype , Humans
5.
Mol Neurodegener ; 16(1): 29, 2021 04 29.
Article in English | MEDLINE | ID: mdl-33926499

ABSTRACT

Alzheimer's disease (AD) is a progressive, neurodegenerative disorder that is characterized by neurodegeneration, cognitive impairment, and an eventual inability to perform daily tasks. The etiology of Alzheimer's is complex, with numerous environmental and genetic factors contributing to the disease. Late-onset AD is highly heritable (60 to 80%), and over 40 risk loci for AD have been identified via large genome-wide association studies, most of which are common variants with small effect sizes. Although these discoveries have provided novel insight on biological contributors to AD, disease-modifying treatments remain elusive. Recently, the concepts of resistance to pathology and resilience against the downstream consequences of pathology have been of particular interest in the Alzheimer's field as studies continue to identify individuals who evade the pathology of the disease even into late life and individuals who have all of the neuropathological features of AD but evade downstream neurodegeneration and cognitive impairment. It has been hypothesized that a shift in focus from Alzheimer's risk to resilience presents an opportunity to uncover novel biological mechanisms of AD and to identify promising therapeutic targets for the disease. This review will highlight a selection of genes and variants that have been reported to confer protection from AD within the literature and will also discuss evidence for the biological underpinnings behind their protective effect with a focus on genes involved in lipid metabolism, cellular trafficking, endosomal and lysosomal function, synaptic function, and inflammation. Finally, we offer some recommendations in areas where the field can rapidly advance towards precision interventions that leverage the ideas of protection and resilience for the development of novel therapeutic strategies.


Subject(s)
Alzheimer Disease/genetics , Age of Onset , Alzheimer Disease/prevention & control , Apolipoproteins E/genetics , Disease Resistance/genetics , Endosomes/physiology , Gene Ontology , Genetic Predisposition to Disease , Genome-Wide Association Study , Homeostasis , Humans , Immunity/immunology , Inflammation , Klotho Proteins/genetics , Klotho Proteins/physiology , Lipid Metabolism , Lysosomes/physiology , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/physiology , Polymorphism, Single Nucleotide , Precision Medicine , Synapses/physiology
6.
J Cyst Fibros ; 19(1): 34-39, 2020 01.
Article in English | MEDLINE | ID: mdl-31126900

ABSTRACT

BACKGROUND: Individuals with cystic fibrosis (CF) experience elevated inflammation in multiple organs, but whether this reflects an inherent feature of CF cells or is a consequence of a pro-inflammatory environment is not clear. METHOD: Using CRISPR/Cas9-mediated mutagenesis of CFTR, 17 subclonal cell lines were generated from Caco-2 cells. Clonal lines with functional CFTR (CFTR+) were compared to those without (CFTR-) to directly address the role of CFTR in inflammatory gene regulation. RESULTS: All lines maintained CFTR mRNA production and formation of tight junctions. CFTR+ lines displayed short circuit currents in response to forskolin, while the CFTR- lines did not. Baseline expression of cytokines IL6 and CXCL8 (IL8) was not different between the lines regardless of CFTR genotype. All lines responded to TNFα and IL1ß by increasing IL6 and CXCL8 mRNA levels, but the CFTR- lines produced more CXCL8 mRNA than the CFTR+ lines. Transcriptomes of 6 CFTR- and 6 CFTR+ lines, before and after stimulation by TNFα, were compared for differential expression as a function of CFTR genotype. While some genes appeared to be differentially expressed simply because of CFTR's absence, others required stimulation for differences to be apparent. CONCLUSION: Together, these data suggest cells respond to CFTR's absence by modulating transcriptional networks, some of which are only apparent when cells are exposed to different environmental contexts, such as inflammation. With regards to inflammation, these data suggest a model in which CFTR's absence leads to a poised, pro-inflammatory state of cells that is only revealed by stimulation.


Subject(s)
Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis , Inflammation/genetics , Caco-2 Cells , Cells, Cultured , Cystic Fibrosis/genetics , Cystic Fibrosis/immunology , Gene Expression Regulation , Gene Regulatory Networks/immunology , Humans , Interleukin-1beta/genetics , Interleukin-6/genetics , Interleukin-8/genetics , Tumor Necrosis Factor-alpha/genetics
7.
Front Neurosci ; 12: 702, 2018.
Article in English | MEDLINE | ID: mdl-30369865

ABSTRACT

The ß-chemokine Ccl5 and its receptors are constitutively expressed in neurons of the murine inner retina. Here, we examined the functional and structural significance of this constitutive Ccl5 signaling on retinal development. We compared outcomes of electrophysiology, ocular imaging and retinal morphology in wild-type mice (WT) and mice with Ccl5 deficiency (Ccl5-/- ). Assessment of retinal structure by ocular coherence tomography and histology revealed slight thinning of the inner plexiform layer (IPL) and inner nuclear layer (INL) in Ccl5-/- mice, compared to WT (p < 0.01). Assessment of postnatal timepoints important for development of the INL (P7 and P10) revealed Ccl5-dependent alterations in the pattern and timing of apoptotic pruning. Morphological analyses of major inner retinal cell types in WT, Ccl5-/- , gustducingfp and gustducingfp/Ccl5-/- mice revealed Ccl5-dependent reduction in GNAT3 expression in rod bipolar cells as well as a displacement of their terminals from the IPL into the GCL. RGC dendritic organization and amacrine cell morphology in the IPL was similarly disorganized in Ccl5-/- mice. Examination of the intrinsic electrophysiological properties of RGCs revealed higher spontaneous activity in Ccl5-/- mice that was characterized by higher spiking frequency and a more depolarized resting potential. This hyperactive phenotype could be negated by current clamp and correlated with both membrane resistance and soma area. Overall, our findings identify Ccl5 signaling as a mediator of inner retinal circuitry during development of the murine retina. The apparent role of Ccl5 in retinal development further supports chemokines as trophic modulators of CNS development and function that extends far beyond the inflammatory contexts in which they were first characterized.

8.
Front Pediatr ; 5: 232, 2017.
Article in English | MEDLINE | ID: mdl-29164084

ABSTRACT

INTRODUCTION: Though the human fetus is exposed to placentally derived human chorionic gonadotropin (hCG) throughout gestation, the role of hCG on the fetal brain is unknown. Review of the available literature appears to indicate that groups of women with higher mean levels of hCG during pregnancy tend to have offspring with lower cerebral palsy (CP) risk. Given that newborn cerebral injury often precedes the development of CP, we aimed to determine whether hCG may protect against the neurodegenerative effects of neonatal brain injury. METHODS: We utilized the Rice-Vannucci model of neonatal cerebral hypoxia-ischemia (HI) in postnatal day 7 mice to examine whether intraperitoneal administration of hCG 15-18 h prior, 1 h after or immediately following HI decrease brain tissue loss 7 days after injury. We next studied whether hCG has pro-survival and trophic properties in neurons by exposing immature cortical and hippocampal neurons to hCG in vitro and examining neurite sprouting and neuronal survival prior and after glutamate receptor-mediated excitotoxic injury. RESULTS: We found that intraperitoneal injection of hCG 15 h prior to HI, but not at or 1 h after HI induction, resulted in a significant decrease in hippocampal and striatal tissue loss 7 days following brain injury. Furthermore, hCG reduced N-methyl-d-aspartate (NMDA)-mediated neuronal excitotoxicity in vitro when neurons were continuously exposed to this hormone for 10 days or when given at the time and following neuronal injury. In addition, continuous in vitro administration of hCG for 6-9 days increased neurite sprouting and basal neuronal survival as assessed by at least a 1-fold increase in MAP2 immunoreactivity and a 2.5-fold increase in NeuN + immunoreactivity. CONCLUSION: Our findings suggest that hCG can decrease HI-associated immature neural degeneration. The mechanism of action for this neuroprotective effect may partly involve inhibition of NMDA-dependent excitotoxic injury. This study supports the hypothesis that hCG during pregnancy has the potential for protecting the developing brain against HI, an important CP risk factor.

9.
Bioorg Med Chem Lett ; 27(22): 4999-5001, 2017 11 15.
Article in English | MEDLINE | ID: mdl-29037946

ABSTRACT

This Letter details our efforts to replace the 3-amino moiety, an essential pharmacophore for M4 PAM activity in most M4 PAMs to date, within the thieno[2,3-b]pyridine core, as the ß-amino carboxamide motif has been shown to engender poor solubility, varying degrees of P-gp efflux and represents a structural alert. A scaffold hopping exercise identified a novel 2,4-dimethylquinoline carboxamide core that provided M4 PAM activity and good CNS penetration without an amino moiety. In addition, MacMillan photoredox catalysis chemistry was essential for construction of the 2,4-dimethylquinoline core.


Subject(s)
Amides/chemistry , Receptor, Muscarinic M4/metabolism , Allosteric Regulation , Amides/chemical synthesis , Amides/pharmacokinetics , Animals , Brain/metabolism , Drug Evaluation, Preclinical , Half-Life , Protein Binding , Pyridines/chemistry , Rats , Rats, Sprague-Dawley , Receptor, Muscarinic M4/chemistry , Structure-Activity Relationship
10.
Bioorg Med Chem Lett ; 27(18): 4274-4279, 2017 09 15.
Article in English | MEDLINE | ID: mdl-28866269

ABSTRACT

This Letter details the discovery and subsequent optimization of a novel M4 PAM scaffold based on an 6-fluoro-4-(piperidin-1-yl)quinoline-3-carbonitrile core, which represents a distinct departure from the classical M4 PAM chemotypes. Optimized compounds in this series demonstrated improved M4 PAM potency on both human and rat M4 (4 to 5-fold relative to HTS hit), and displayed attractive physicochemical and DMPK profiles, including good CNS penetration (rat brain:plasma Kp=5.3, Kp,uu=2.4; MDCK-MDR1 (P-gp) ER=1.1).


Subject(s)
Central Nervous System/drug effects , Drug Discovery , Piperidines/pharmacology , Quinolines/pharmacology , Receptor, Muscarinic M4/antagonists & inhibitors , Animals , Dose-Response Relationship, Drug , Humans , Molecular Structure , Piperidines/chemical synthesis , Piperidines/chemistry , Quinolines/chemical synthesis , Quinolines/chemistry , Rats , Structure-Activity Relationship
11.
ACS Med Chem Lett ; 8(9): 919-924, 2017 Sep 14.
Article in English | MEDLINE | ID: mdl-28947937

ABSTRACT

Herein, we detail the optimization of the mGlu2 negative allosteric modulator (NAM), VU6001192, by a reductionist approach to afford a novel, simplified mGlu2 NAM scaffold. This new chemotype not only affords potent and selective mGlu2 inhibition, as exemplified by VU6001966 (mGlu2 IC50 = 78 nM, mGlu3 IC50 > 30 µM), but also excellent central nervous system (CNS) penetration (Kp = 1.9, Kp,uu = 0.78), a feature devoid in all previously disclosed mGlu2 NAMs (Kps ≈ 0.3, Kp,uus ≈ 0.1). Moreover, this series, based on overall properties, represents an exciting lead series for potential mGlu2 PET tracer development.

12.
ACS Med Chem Lett ; 8(9): 925-930, 2017 Sep 14.
Article in English | MEDLINE | ID: mdl-28947938

ABSTRACT

Herein, we detail the optimization of the mGlu3 NAM, VU0650786, via a reductionist approach to afford a novel, simplified mGlu3 NAM scaffold that engenders potent and selective mGlu3 inhibition (mGlu3 IC50 = 245 nM, mGlu2 IC50 > 30 µM) with excellent central nervous system penetration (rat brain/plasma Kp = 1.2, Kp,uu = 0.40). Moreover, this new chemotype, exemplified by VU6010572, requires only four synthetic steps and displays improved physiochemical properties and in vivo efficacy in a mouse tail suspension test (MED = 3 mg/kg i.p.).

13.
Bioorg Med Chem Lett ; 27(15): 3576-3581, 2017 08 01.
Article in English | MEDLINE | ID: mdl-28633897

ABSTRACT

This letter describes the synthesis and structure activity relationship (SAR) studies of structurally novel M4 antagonists, based on a 3-(4-aryl/heteroarylsulfonyl)piperazin-1-yl)-6-(piperidin-1-yl)pyridazine core, identified from a high-throughput screening campaign. A multi-dimensional optimization effort enhanced potency at human M4 (hM4 IC50s<200nM), with only moderate species differences noted, and with enantioselective inhibition. Moreover, CNS penetration proved attractive for this series (rat brain:plasma Kp=2.1, Kp,uu=1.1). Despite the absence of the prototypical mAChR antagonist basic or quaternary amine moiety, this series displayed pan-muscarinic antagonist activity across M1-5 (with 9- to 16-fold functional selectivity at best). This series further expands the chemical diversity of mAChR antagonists.


Subject(s)
Brain/metabolism , Muscarinic Antagonists/pharmacology , Muscarinic Antagonists/pharmacokinetics , Pyridazines/pharmacology , Pyridazines/pharmacokinetics , Receptor, Muscarinic M4/antagonists & inhibitors , Animals , Brain/drug effects , CHO Cells , Cricetulus , Humans , Muscarinic Antagonists/chemistry , Piperazine , Piperazines/chemistry , Piperazines/pharmacokinetics , Piperazines/pharmacology , Pyridazines/chemistry , Rats , Receptor, Muscarinic M4/metabolism , Structure-Activity Relationship
14.
Bioorg Med Chem Lett ; 27(13): 2990-2995, 2017 07 01.
Article in English | MEDLINE | ID: mdl-28522253

ABSTRACT

This letter details the continued chemical optimization of a novel series of M4 positive allosteric modulators (PAMs) based on a 5-amino-thieno[2,3-c]pyridazine core by incorporating a 3-amino azetidine amide moiety. The analogs described within this work represent the most potent M4 PAMs reported for this series to date. The SAR to address potency, clearance, subtype selectivity, CNS exposure, and P-gp efflux are described. This work culminated in the discovery of VU6000918, which demonstrated robust efficacy in a rat amphetamine-induced hyperlocomotion reversal model at a minimum efficacious dose of 0.3mg/kg.


Subject(s)
Amides/pharmacology , Azetidines/pharmacology , Receptor, Muscarinic M4/antagonists & inhibitors , Allosteric Regulation/drug effects , Amides/chemical synthesis , Amides/chemistry , Animals , Azetidines/chemical synthesis , Azetidines/chemistry , Disease Models, Animal , Dose-Response Relationship, Drug , Humans , Molecular Structure , Rats , Structure-Activity Relationship
15.
Bioorg Med Chem Lett ; 27(11): 2479-2483, 2017 06 01.
Article in English | MEDLINE | ID: mdl-28427812

ABSTRACT

This letter describes the synthesis and structure activity relationship (SAR) studies of structurally novel M4 antagonists, based on a 4,6-disubstituted core, identified from a high-throughput screening campaign. A multi-dimensional optimization effort enhanced potency at both human and rat M4 (IC50s<300nM), with no substantial species differences noted. Moreover, CNS penetration proved attractive for this series (brain:plasma Kp,uu=0.87), while other DMPK attributes were addressed in the course of the optimization effort, providing low in vivo clearance in rat (CLp=5.37mL/min/kg). Surprisingly, this series displayed pan-muscarinic antagonist activity across M1-5, despite the absence of the prototypical basic or quaternary amine moiety, thus offering a new chemotype from which to develop a next generation of pan-muscarinic antagonist agents.


Subject(s)
Muscarinic Antagonists/chemical synthesis , Pyrimidines/chemistry , Receptor, Muscarinic M4/antagonists & inhibitors , Animals , Brain/metabolism , Humans , Inhibitory Concentration 50 , Muscarinic Antagonists/chemistry , Muscarinic Antagonists/pharmacokinetics , Protein Binding , Pyrimidines/chemical synthesis , Pyrimidines/pharmacokinetics , Rats , Receptor, Muscarinic M4/metabolism , Receptors, Muscarinic/chemistry , Receptors, Muscarinic/genetics , Receptors, Muscarinic/metabolism , Recombinant Proteins/biosynthesis , Recombinant Proteins/chemistry , Structure-Activity Relationship
16.
ACS Med Chem Lett ; 8(2): 233-238, 2017 Feb 09.
Article in English | MEDLINE | ID: mdl-28197318

ABSTRACT

Herein, we report the structure-activity relationships within a series of potent, selective, and orally bioavailable muscarinic acetylcholine receptor 4 (M4) positive allosteric modulators (PAMs). Compound 6c (VU0467485) possesses robust in vitro M4 PAM potency across species and in vivo efficacy in preclinical models of schizophrenia. Coupled with an attractive DMPK profile and suitable predicted human PK, 6c (VU0467485) was evaluated as a preclinical development candidate.

17.
Bioorg Med Chem Lett ; 27(2): 171-175, 2017 01 15.
Article in English | MEDLINE | ID: mdl-27939174

ABSTRACT

This letter describes the chemical optimization of a novel series of M4 positive allosteric modulators (PAMs) based on a 5-amino-thieno[2,3-c]pyridazine core, developed via iterative parallel synthesis, and culminating in the highly utilized rodent in vivo tool compound, VU0467154 (5). This is the first report of the optimization campaign (SAR and DMPK profiling) that led to the discovery of VU0467154, and details all of the challenges faced in allosteric modulator programs (steep SAR, species differences in PAM pharmacology and subtle structural changes affecting CNS penetration).


Subject(s)
Pyridazines/pharmacology , Receptor, Muscarinic M4/agonists , Thiophenes/pharmacology , Animals , Humans , Ligands , Nucleoside Transport Proteins/metabolism , Pyridazines/administration & dosage , Pyridazines/chemical synthesis , Pyridazines/pharmacokinetics , Rats, Sprague-Dawley , Structure-Activity Relationship , Thiophenes/administration & dosage , Thiophenes/chemical synthesis , Thiophenes/pharmacokinetics
SELECTION OF CITATIONS
SEARCH DETAIL
...